SymBio Pharmaceuticals Limited (TYO:4582)

Market Cap	5.63B -26.4%
Revenue (ttm)	1.28B -39.7%
Net Income	-5.86B
EPS	-106.24
Shares Out	72.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	668,500
Open	81.00
Previous Close	79.00
Day's Range	77.00 - 82.00
52-Week Range	75.00 - 229.00
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 91
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4582

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.70% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.